The E6 proteins from the high-risk human papillomavirus (HPV) types have previously been shown to target a number of PDZ domain-containing proteins for proteasome-mediated degradation. These include the hDlg tumour suppressor and the MAGI-1 protein. In this study we show that high-risk HPV E6 proteins also target the related MAGI-2 and MAGI-3 proteins for degradation. Moreover, we show that the interaction is specific to one PDZ domain, and that co-expression of this domain can protect each of the full-length MAGI proteins from E6-mediated degradation. These data provide clear indicators for the potential design of compounds that could specifically inhibit the interaction of oncogenic HPV E6 proteins with an important class of target proteins.
Introduction
The membrane-associated guanylate kinase homologues (MAGUKs) are large proteins that contain a number of protein interaction domains, allowing them to act as molecular scaffolds in the formation of multimolecular complexes. These include WW or SH3 domains, a Guanylate Kinase (GuK) homology domain and several PDZ domains (Ponting and Phillips, 1995; Saras and Heldin, 1996; Kim, 1997; Kim et al., 1998) . These proteins are found particularly at areas of cellcell contact, such as synaptic junctions in neurons and at the tight junctions in epithelial cells (Gomperts, 1996; Mitic and Anderson, 1998; Craven and Bredt, 1998) and are thought to act in signalling pathways. The PDZ domains are stretches of 80 -90 amino acids (Ponting and Phillips, 1995; Fanning and Anderson, 1999 ) that bind with high affinity to specific sequences (T/SXV) (Songyang et al., 1997) , usually found in the extreme carboxy termini of their target proteins. The binding of certain of these sequences has been reported to be modified by phosphorylation (Ku¨hne et al., 2000; Tolkacheva et al., 2001; Choi et al., 2002) and it seems likely that this may be a more general mechanism for the temporal or spatial control of such protein interactions. PDZ binding motifs have been identified in a number of virus proteins that are associated with oncogenesis, including the HTLV-1 Tax protein, Adenovirus 9 E4-ORF1 protein and the E6 proteins of high-risk HPV types (Lee et al., 1997) . The fact that a number of PDZ-containing proteins have been identified as being common targets of these oncogenic virus proteins indicates that they may well belong to conserved pathways that are subverted by diverse viruses during oncogenic transformation. This is certainly probable in the case of hDlg, which is targeted by both Adenovirus 9 E4-ORF1 and HPV E6 (Lee et al., 1997; Kiyono et al., 1997; Gardiol et al., 1999) . Dlg has been shown to be essential for the regulation of cell growth and polarity in Drosophila (Bilder et al., 2000) and is a potential tumour suppressor, as is hScrib, another PDZ domain-containing target of HPV E6 (Nakagawa and Huibregtse, 2000) . More recently E6s have been shown to target MAGI-1 -MAGUK with inverted domain structure (Glaunsinger et al., 2000) . MAGI-1 is localized at tight junctions in epithelial cells (Dobrosotskaya et al., 1997; Ide et al., 1999) , and may be involved in signalling since it has nuclear localization signals at the carboxy terminus (Dobrosotskaya et al., 1997) ; it also complexes with b-catenin (Dobrosotskaya and James, 2000) , which is disregulated in many latestage cancers (reviewed in Polakis, 1999) . Interestingly, the HPV-18 E6 interacts more strongly with hDlg and with MAGI-1 than HPV-16 E6 (Glaunsinger et al., 2000; Pim et al., 2000; Thomas et al., 2001) , and this correlates with the greater likelihood of recurrence and metastasis of HPV-18-containing cervical tumours (reviewed in Franco, 1992) .
MAGI-1 is closely related to, and shares considerable homology with, the MAGI-2 and MAGI-3 proteins. Both of these proteins were identified in yeast two-hybrid assays as binding to the PTEN tumour suppressor (Wu et al., 2000a,b) . PTEN is a down-regulator of the PKB/Akt kinase regulation pathway (Li et al., 1998; Downward, 1998; Stambolic et al., 1998) , upregulation of which is associated with cell survival and proliferation (reviewed in Marte and Downward, 1997; Downward, 1998) . It has a carboxy terminal PDZ-binding motif, and this region has been shown to be involved in PTEN's tumour suppressive activity (Georgescu et al., 1999, Tolkacheva and Chan, 2000; Leslie et al., 2000 Leslie et al., , 2001 ). This region is also subject to phosphorylation (Adey et al., 2000; Vazquez et al., 2000; Torres and Pulido, 2001) , which affects PTEN's binding to MAGI-2 (Tolkacheva et al., 2001) .
The high risk HPV E6 proteins have been shown to be involved in de-regulating aspects of cell homeostasis related to cell growth and polarity in response to cell contact, through the degradation of hDlg (Gardiol et al., 1999; Ku¨hne et al., 2000; Pim et al., 2000; and MAGI-1 (Glaunsinger et al., 2000; Thomas et al., 2001) . Given that MAGI-2 and MAGI-3 are highly homologous to MAGI-1, and that they are associated with such fundamental growth control pathways, it was obviously of interest to determine whether the high-risk HPV E6 proteins are able to interact with them. In this study we have shown that MAGI-2 and MAGI-3 are extremely susceptible to HPV E6-induced degradation, both in vitro and in vivo. We have mapped the region of interaction to the PDZ1 domain of both proteins, and have shown that this region, when expressed individually, can block the E6-induced degradation of the MAGI proteins.
Results
High-risk HPV E6 proteins specifically target MAGI-2 and MAGI-3 for degradation in vitro We had previously shown that the E6 proteins from the high-risk mucosal HPV types can induce the degradation of MAGI-1 (Glaunsinger et al., 2000; Thomas et al., 2001) . Since there is considerable homology between MAGI-1 and the MAGI-2 and MAGI-3 proteins, which have been associated with the PTEN tumour suppressor (Wu et al., 2000a,b) , we wished to determine whether the HPV E6 proteins had any effect upon MAGI-2 and MAGI-3 stability.
To address this question we first performed degradation assays, as described previously (Glaunsinger et al., 2000) . In vitro translated MAGI proteins were incubated with in vitro translated HPV-16 E6 and HPV-18 E6 at a MAGI to E6 ratio of 1 : 3 (as determined from PhosphorImager analysis of the translates). The results of these assays are shown in Figure 1a : as we would expect from previous work (Glaunsinger et al., 2000; Thomas et al., 2001) , MAGI-1 is degraded readily in the presence of HPV-18 E6 and, somewhat less readily, in the presence of HPV-16 E6. It is also clear that MAGI-2 and, particularly, MAGI-3 are even more susceptible than MAGI-1 to HPV E6-induced degradation in vitro.
To confirm that the degradation of the MAGI proteins is caused specifically by the presence of HPV E6, we performed a further degradation assay in vitro, using HPV-18 E6 at either a lower (2 : 1) or a higher (5 : 1) ratio to the MAGI-2 and MAGI-3 proteins. It can be seen in Figure 1b In vitro translated MAGI proteins were incubated with in vitro translated E6 proteins for 15, 30 or 60 min at 308C. Remaining protein was immunoprecipitated and analysed by SDS -PAGE (7.5%) and autoradiography. The lower panel shows the comparative levels of E6 inputs in each reaction tube, analysed by SDS -PAGE (12%) and autoradiography. (b) The degradation of MAGI-2 and MAGI-3 is dependent upon the concentration of HPV-18 E6. An in vitro degradation assay was performed as before, the ratios of MAGI proteins to HPV-18 E6 protein are shown. MAGI-2 was precipitated with anti-HA antibody, and MAGI-3 with anti-V5 antibody MAGI-2 and MAGI-3 proteins, we wished to determine whether this was due to proteasomal degradation, as has been reported for other targets of HPV E6 proteins such as p53, Bak, hDlg and MAGI-1 (Scheffner et al., 1990; Thomas and Banks, 1998; Gardiol et al., 1999; Glaunsinger et al., 2000) . To investigate this, 293 cells were transfected with plasmids expressing HPV-18 E6, plus either MAGI-2 ( Figure 2 , upper panels) or MAGI-3 (Figure 2 , lower panels). After 22 h they were treated, or not, with 50 mM of the LLnL proteasome inhibitor for 2 h, the proteins were then extracted and the presence of each MAGI protein was detected by SDS -PAGE and Western blotting. It is clear that the levels of both MAGI-2 and MAGI-3 are severely reduced in the presence of HPV-18 E6 and that these are, to a certain extent, rescued by the presence of LLnL. Similar results were seen using the CBZ proteasome inhibitor (data not shown). Thus, these data, together with those in Figure 1 , define MAGI-2 and MAGI-3 as being two potential new targets of the oncogenic HPV E6 proteins.
Homology within the MAGI protein sequences
Having shown previously that the MAGI-1 PDZ1 domain is necessary for its HPV-18 E6-induced degradation , we wished to compare the sequences of the PDZ1 domains of the MAGI-2 and MAGI-3 proteins (Wu et al., 2000a,b) . These were aligned using Jellyfish software (Biowire) and are shown in Figure 3 . We included the sequence of MAGI-1 PDZ5, which shares most homology with MAGI-1 PDZ1 (Dobrosotskaya et al., 1997) but is not bound by HPV E6 proteins . The boxed regions indicate PDZ-defining motifs, and the stars and diamonds indicate amino acid residues that are predicted, from modelling other PDZ-binding interactions, to be in contact with the similarly labelled amino acid residues in the HPV-18 E6 binding motif (Cho et al., 1992; Doyle et al., 1996; Morais Cabral et al., 1996) . It is clear that (boxed regions aside) there is considerable homology (black lettering) between the PDZ1 domains of MAGI-1, MAGI-2 and MAGI-3, which is not shared by the MAGI-1 PDZ5. It therefore seemed possible that PDZ1 might also be the HPV E6 recognition target on MAGI-2 and MAGI-3.
PDZ1 of MAGI-3 is required for HPV-18 E6-induced degradation
To define the region of the interaction of HPV E6 proteins with these new target proteins, we first constructed a series of truncation mutants of MAGI-3; a cartoon of these is shown in Figure 4a . Plasmids expressing these mutants were then transfected into 293 cells, either with or without plasmids expressing HPV-18 E6. After 24 h the cells were harvested and the proteins analysed by SDS -PAGE and Western blotting; the results are shown in Figure 4b . It is clear from this assay that the mutants 1A, 3A and 4BL, which retain PDZ1, are all susceptible to degradation in the presence of HPV-18 E6. However, mutant 4A, which lacks the amino terminal part of the protein, including PDZ1, is completely stable in the presence of HPV-18 E6. These data indicate that the region of MAGI-3 required for E6-induced degradation lies between amino acid residues 407 and 542 and, as is the case with MAGI-1 , the PDZ1 domain of MAGI-3 appears to be essential for its susceptibility to HPV-18 E6-induced degradation.
In vivo inhibition of MAGI-3 degradation
Having shown that the PDZ1 of MAGI-3 is required for its E6-induced degradation, we were interested in determining whether this domain could be used to specifically inhibit E6's ability to induce degradation of its target proteins in vivo. To address this, 293 cells were transfected with plasmids expressing MAGI-3, together with plasmids expressing either HPV-16 or HPV-18 E6. These were co-transfected with plasmids expressing the PDZ domains 1, 2, 3 or 4 of MAGI-3 as GST fusion proteins. After 24 h the cells were harvested and the proteins analysed by Western blot. As can be seen in Figure 5 , the degradation of MAGI-3 in the presence of HPV-16 and HPV-18 E6 is inhibited specifically by the co-expression of GST-PDZ1, but not by co-expression of the other GST- PDZs. This provides further evidence for the specific interaction of the MAGI proteins' PDZ1 domains with HPV E6 oncoproteins. Interestingly, HPV-16 E6-induced degradation does not appear to be blocked as well as HPV-18 E6-induced degradation, which may reflect the more effective binding motif of HPV-18 E6 .
We were next interested in determining whether the GST-PDZ1 is itself a target for degradation, in which case the inhibition could be the result of competition for components of the degradation machinery, and not blocking the E6/target protein interaction per se. If this were the case it would also obviously negate the usefulness of these data in defining a strategy for the development of any potential therapeutic agent. To rule out this possibility, we co-transfected the plasmids expressing the GST-PDZ fusion proteins with plasmids expressing HPV-18 E6. After 24 h the cells were harvested, and the proteins analysed by SDS -PAGE and Western blotting using an anti-GST antibody. The results are shown in Figure 6 where it is clear that there is no change in the stability of the GST-PDZ proteins in the presence of HPV-18 E6. This suggests that the viral protein binds specifically to PDZ1, but that this is not sufficient to allow it to induce degradation. This further suggests that the ubiquitin-protein ligase involved in the degradation of the MAGI proteins does not ubiquitinate residues in this region, but requires additional protein sequences within the MAGI proteins; based on the deletion analysis in Figure 4 , these are most likely to be between the WW domains and the start of PDZ1.
GST-PDZ1 specifically inhibits the HPV-18 E6-induced degradation of PDZ-containing targets
Having shown that the GST-PDZ proteins are stable in the presence of HPV-18 E6, and that PDZ1 could inhibit the degradation of MAGI-3, we wished to Figure 3 Sequence alignment of the PDZ1 domains of the MAGI proteins. The PDZ1 domains of MAGI-1 (aa residues 435 -550), MAGI-2 (aa residues 409 -524) and MAGI-3 (aa residues 418 -533) are aligned. MAGI-1 PDZ5 (aa residues 1020 -1121), which is not bound by E6, is included for comparison. The PDZ-binding motif of HPV-18 is included: the stars and diamonds identify amino acids that are predicted to be in contact during binding. The amino acid residues that define PDZ domains are boxed. Bold typeface indicates residues conserved in all three proteins, red indicates those conserved in two out of three, non-conserved are in blue determine whether this was specific to MAGI-3, or a more global effect. We therefore transfected GST-PDZexpressing plasmids, together with those expressing HPV-18 E6 and its most famous target protein, p53, into p53-null Saos-2 cells. The proteins were extracted and analysed by Western blot. It can be seen in Figure  7a that none of the GST-PDZ domains has any effect upon the E6-induced degradation of p53. This clearly shows that the inhibitory effect of MAGI-3 PDZ1 is not a general disabling of E6 function. It was then of interest to determine whether PDZ1 could protect other PDZ-containing targets from degradation. To that end, 293 cells were transfected with the GST-PDZexpressing plasmids, together with pCDNA : HPV-18 E6 and either pCDNA : MAGI-2 or pCDNA : MAGI-3. The Western blots are shown in Figure 7b which confirms that GST-PDZ1, but not GST-PDZ2, 3 or 4, can inhibit the HPV-18 E6-induced degradation of MAGI-3 and also shows that MAGI-2 is similarly protected.
To determine whether MAGI-1 can be similarly protected, an in vitro degradation assay was performed. This was done as before, but the in vitro translated HPV-18 E6 was pre-incubated at 308C for 20 min with the in vitro translated PDZ domains of MAGI-2, prior to the addition of in vitro translated MAGI-1. The assay was incubated and immunoprecipitated as described for Figure 1a , and the results are shown in Figure 7c . It is clear that only PDZ1 is capable of inhibiting the degradation of MAGI-1 in vitro. Similar results are seen with MAGI-2 and MAGI-3 (data not shown).
These results demonstrate that the PDZ1 domain can be used effectively to block the activity of E6 in targeting PDZ domain-containing proteins for degradation. In addition, the high degree of specificity is confirmed by the lack of any effect upon the E6-targeted degradation of p53.
Discussion
In this study we present data defining the MAGUK proteins, MAGI-2 and MAGI-3, as new cellular targets of the mucosal oncogenic HPV E6 proteins. We show that oncogenic E6 proteins can induce their degradation at least partly through the proteasome. By a series of mutational analyses we show conclusively that the PDZ1 domain of MAGI-3 is absolutely required for its targeting by E6, but that the PDZ1 alone is not degraded in the presence of E6. We also show that the presence of PDZ1 can specifically inhibit the E6-induced degradation of its PDZ-containing targets, but not the degradation of p53, thus providing exciting pointers for the design of highly specific inhibitors of E6 function.
We had previously shown that the MAGI-1 protein is an extremely good substrate for E6-mediated degradation, better, indeed, than p53 . We had also previously shown that, in contrast to the case with p53 (Scheffner et al., 1990) , HPV-18 E6 binds more strongly to, and induces degradation of, MAGI-1 and hDlg more efficiently than HPV-16 E6 (Glaunsinger et al., 2000; Pim et al., 2000) . This is caused by HPV-18 E6 having a perfect PDZ-binding motif, while that of HPV-16 is suboptimal . The results reported here demonstrate that both MAGI-2 and MAGI-3 are extremely susceptible to E6-induced degradation, and they also show that HPV-18 E6 is the more effective inducer of degradation, both in vitro and in vivo. In addition, the levels of MAGI-2 and MAGI-3 proteins can be restored to a certain extent by treatment of the cells with the proteasome inhibitor LLnL, indicating that proteasomal degradation is occurring. However, LLnL has no effect upon the levels of either MAGUK in the absence of HPV-18 E6, suggesting either that MAGI-2 and MAGI-3 proteins are relatively stable in these cells in the absence of E6, or that they are not normally turned over by the proteasome. It should be noted here that MAGI-2 has so far only been detected in brain tissue (Wood et al., 1998; Shoji et al., 2000) so its susceptibility to E6 degradation may be a result of its homology to MAGI-1 and MAGI-3, however no analysis of MAGI-2 expression in epidermis has yet been reported.
Having shown that both MAGI-2 and MAGI-3 are targeted for degradation by E6, we were obviously interested in determining the regions of interaction. We have previously shown that the PDZ1 domain of MAGI-1 is the specific site bound by the oncogenic HPV E6s and in the case of MAGI-3 the same region appears to be required. Thus co-expression of a series of MAGI-3 deletion mutants with HPV-18 E6 clearly showed that the PDZ1 domain, and a short region upstream of it, are required for HPV-18 E6 to induce MAGI-3 degradation. Since mutants of E6 with defects in PDZ-binding, or lacking a PDZ-binding motif, cannot bind to MAGI-1 (Pim et al., 2000) , it seems clear that E6 itself binds the PDZ1 domain. However, the MAGI-2 and MAGI-3 proteins appear to be quite stable in the absence of E6, as was shown in the initial in vivo analysis, in which there was no increased stability of either protein with proteasome inhibitor. Therefore any potential therapeutic strategies to prevent E6 inducing their degradation need only interfere with the E6 interaction, and indeed this would reduce the possibility of interfering with normal activities of the proteins within the cell. We therefore focused our attention on the effects of the individual PDZ domains upon the degradation induced by HPV-18 E6. When we looked at the in vivo activity of the PDZ domains expressed as GST fusion proteins, it was clear that the PDZ1 domain was the only one capable of inhibiting the degradation of MAGI-3 by either HPV-16 or HPV-18 E6. Thus it appeared that MAGI-3 PDZ1 protects the natural protein from degradation induced by E6.
It was possible that the PDZ1, since it interacts with E6, was also being degraded and that the protection of MAGI-3 occurred through competition for the cellular degradation machinery and not by specific inhibition of the MAGI-3 degradation. However, it is clear from the in vivo analysis of GST-PDZ stability in the presence of E6 that the GST-PDZ domains are not targets for E6-induced degradation, suggesting that the effect might be through direct competition for the PDZ-binding motif. Further analysis provided support for this hypothesis, since, in vivo, GST-PDZ1 of MAGI-3 can inhibit the HPV-18 E6-induced degradation, not only of MAGI-3, but also of MAGI-2; and the MAGI-2 PDZ1 is similarly effective with respect to protection of MAGI-1 in vitro. In contrast, the degradation of p53 is completely unaffected by the presence of any of the GST-PDZ domains, and this is consistent with a number of studies showing that the extreme carboxy terminus of the HPV E6 proteins, containing the PDZbinding motif, is not involved in interacting with p53 (see reviews: Thomas et al., 1999; Pim et al., 2001; . These data provide further support for the notion that GST-PDZ1 interacts specifically with high-risk HPV E6 proteins and thus blocks their interaction with their natural PDZ domain-containing targets. It is tempting to speculate that the E6 proteins, which are expressed at very low levels Banks et al., 1987) , may only bind to the MAGI proteins when PDZ1 has been vacated by its natural ligand(s); this, in turn, might suggest that a MAGI protein with an empty PDZ1 could have a negative effect upon viral replication. A natural ligand of MAGI-1 has been reported: a Rho family nucleotide exchange factor, mNET1, was identified by two-hybrid to bind MAGI-1 PDZ1 (Dobrosotskaya, 2001) . How these ligands might affect the virus is not yet clear, but the relationship of nucleotide exchange factors to the DNA replication readiness of the cell could be a factor.
In this study, we define MAGI-2 and MAGI-3 as being two new targets of the high-risk HPV E6 proteins. We show that E6 very efficiently targets both proteins for degradation, at least in part via the proteasome. This activity of E6 can be specifically blocked by co-expression of MAGI-3 PDZ1, providing a clear indication of the potential for design of specific chemotherapeutic agents.
Materials and methods

Cells and transfections
293 cells and Saos-2 cells were maintained in Dulbecco's modified medium supplemented with 10% foetal calf serum, and transfections were performed using the standard calcium phosphate precipitation method (Wigler et al., 1979) .
Western blots
Western blots were developed by the ECL enhanced chemiluminescence method (Amersham) according to the manufacturer's instructions.
Plasmid constructs
HPV-16, HPV-18 and p53 sequences were cloned into pSP64 for in vitro expression and into pCDNA3.1 for expression in vivo as has been described previously (Pim et al., 1994) . MAGI-1 was cloned into pCDNA3.1 for in vitro expression and has been described previously (Glaunsinger et al., 2000) . MAGI-2 (Accession number AF038563) (Wu et al., 2000a , Shoji et al., 2000 was cloned into pCDNA3.1 with an amino terminal HA epitope tag. MAGI-3 (Accession number AF257238) (Wu et al., 2000b) was cloned into the pCDNA3.1/V5-His-TOPO plasmid (Invitrogen) with tandem V5 and 6xHis epitope tags at the carboxy terminus. The PDZ domains of MAGI-2 were cloned into pCDNA.His vector (Invitrogen) with tandem eXpress and 6xHis epitope tags at the amino termini.
MAGI-3 deletion mutants were constructed as follows: fulllength MAGI-3 was PCR amplified with an amino terminal FLAG tag and cloned into the HindIII/SalI sites of pEGFP-N3 (Clontech), using the 5' primer AAGCTTATGGACTA-CAAAGAC GATGACGACAAGACG CGTATGTCGAAG-ACGCTGAAGAAG (HindIII site/FLAG tag/MluI site/ MAGI-3 amino terminus) and the 3' primer GTCGACATG-TTGCTCGGGTTTCACGTAGGAG (carboxy terminus of MAGI-3 without stop codon/SalI site) to create a fusion construct pEGFP-N3 MAGI-3. MAGI-3 deletion mutants fused to EGFP were made by PCR amplification of the desired regions: 1A contains amino acid residues (aa) G106-H1050, 3A contains aa Q407-H1050, 4A contains aa Q542-H1050, and 4BL contains aa M1-S594. The products were digested and inserted into the MluI/SalI sites of pEGFP-N3 MAGI-3, from which full-length MAGI-3 had been excised using the MluI/SalI sites, such that the deletion mutants would retain an amino terminal FLAG tag and have EGFP on the carboxy terminus.
Expression constructs containing individual PDZ domains of MAGI-3 were constructed via PCR, using the full-length pCDNA3.1 : MAGI-3 (described above) as the template. PCR products of PDZ1 (aa 417 -535), PDZ2 (aa 584 -707), PDZ3 (aa 741 -840), and PDZ4 (aa 870 -976), with flanking 5' BamHI and 3' NotI sites were cloned into the BamHI/NotI sites of pEBG (Sanchez et al., 1994) , creating in-frame fusion at the carboxy terminus of GST.
Antibodies
MAGI-1, MAGI-2 and MAGI-3 were immunoprecipitated after the in vitro degradation assays shown in Figures 1a and  7c , using a rabbit polyclonal anti-WW antibody, raised against a GST fusion protein with the WW domains of MAGI-1, as described previously (Glaunsinger et al., 2000) . In vitro translated MAGI-2 was detected with an anti-HA monoclonal antibody (Boehringer) and in vitro translated MAGI-3 was detected with an anti-V5 monoclonal antibody (Invitrogen) in Figure 1b .
Transfected MAGI-3 was detected in Western blots with an anti-V5 monoclonal antibody (Invitrogen); the MAGI-3 deletion mutants were detected using an anti-GFP polyclonal antibody (Invitrogen) and the MAGI-3 GST-PDZ fusion proteins were detected with a rabbit polyclonal anti-GST antibody.
Transfected MAGI-2 was detected in Western blots with an anti-HA monoclonal antibody (Boehringer).
p53 was detected in Western blots and immunoprecipitated from in vitro degradation assays with pAb1801 anti-p53 monoclonal antibody (Banks et al., 1986) .
b-galactosidase was detected in Western blots with an antib-galactosidase monoclonal antibody (Promega).
In vitro degradation assays
The proteins were translated in vitro in rabbit reticulocyte lysate, using the Promega TNT system according to the manufacturer's instructions and were radiolabelled with 35 [S]-cysteine (Amersham, UK). The efficiency of translation was monitored by analysing a 1 ml aliquot of each translate by SDS -PAGE and PhosphorImager analysis. The assays were then performed as described previously (Glaunsinger et al., 2000) . Briefly, the translated proteins were mixed at the required ratios (as calculated from the PhosphorImager analysis and the number of cysteine residues in the protein), and incubated at 308C, aliquots were removed from the reaction mixture at the time-points indicated. All volumes were equalized using water-primed reticulocyte lysate TNT mix. After incubation the remaining MAGI proteins were immunoprecipitated using the anti-WW antiserum and analysed by SDS -PAGE (7.5%). A 1 ml aliquot was taken from each of the reaction mixes before incubation and analysed by SDS -PAGE (12%) to confirm equal levels of E6 or PDZ domain loading.
